Hardy Diagnostics Now Offers the BioCode® MDx-3000
Retrieved on:
Montag, März 14, 2022
Federal Food, Drug, and Cosmetic Act, Gram, Partnership, NL63, Laboratory, RPP, OC43, STEC, Campylobacter, Hair, BMB, Emergency Use Authorization, Severe acute respiratory syndrome coronavirus 2, Bacteria, Stanford University v. Roche Molecular Systems, Inc., Hardy, Escherichia coli, Hardy Diagnostics, Allergy, FDA, EIEC, EUA, Infection, EAEC, GLOBE, Hematology, Autoimmune disease, LIS, Microbiology, ETEC, PCR, Automation, 1993 Jack in the Box E. coli outbreak, RSV, Vibrio parahaemolyticus, Culture, GPP, Immunochemistry, Nomenclature codes, IVD, Fungus, Medical degree, Molecular Probes, Yersinia enterocolitica, Virus, COVID, HKU1, Laboratory information management system, CE marking, Hospital, Technology, COVID-19, Diagnosis, Vaccine, Medical device, Coronavirus
"Applied BioCode is thrilled to partner with Hardy Diagnostics," said Winston Ho, President of Applied BioCode.
Key Points:
- "Applied BioCode is thrilled to partner with Hardy Diagnostics," said Winston Ho, President of Applied BioCode.
- "We look forward to working with the Hardy Diagnostics team to expand our reach in hospitals and reference laboratories in the US."
- Hardy Diagnostics is an FDA-licensed manufacturer of medical devices for microbiology testing with an ISO 13485 certified Quality Management System.
- Hardy Diagnostics distributes more than 13,000 products, services more than 10,000 laboratories and exports to more than 80 foreign distributors.